# Change Agents Corporation.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Change Agents Corporation.).

## Overview

Change Agents Corporation is a U.S.-based technology and life-sciences company developing AI software, cellular-therapy intellectual property, and diagnostic products. Its portfolio includes an AI-driven automated video production platform, the KetoAir breathalyzer, QTY-code protein design applications, CAR-T technology, and generative-AI publishing and software initiatives, with operations and corporate entities in the United States and China.

## Products & services

• Agentic AI and automated video production SaaS
• KetoAir ketone breathalyzer device
• QTY-code protein design and cytokine receptor IP
• CAR-T cellular therapy technology
• Generative-AI publishing and software IP

- **AI Software** (30%) — Agentic AI systems and an automated video production platform target consumers and small businesses.
- **Diagnostic Devices** (30%) — KetoAir is a breathalyzer product designed to measure ketosis for diabetes and obesity-related use cases.
- **Cellular Therapy IP** (20%) — The company advances QTY-code protein design and CAR-T technology patent applications.
- **Generative AI IP** (15%) — Generative-AI publishing and software projects expand the company’s technology portfolio.
- **Other Commercial Activities** (5%) — Historical activities included commercial real estate operations at the New Jersey headquarters.

- Agentic AI and automated video production SaaS
- KetoAir ketone breathalyzer device
- QTY-code protein design and cytokine receptor IP
- CAR-T cellular therapy technology
- Generative-AI publishing and software IP

## Customers

The company targets consumers and small businesses through its planned AI software offering, while KetoAir is marketed to individuals managing ketosis, diabetes, or obesity-related goals. Distribution also may reach healthcare-oriented users and wellness customers through the KetoAir website, social media, and territorial distributors. Its cellular-therapy and protein-design assets are oriented toward biotechnology, pharmaceutical, and research collaborators rather than direct mass-market buyers.

- **Consumers** (primary) — Buy AI video-production tools and KetoAir for personal content creation or ketosis monitoring.
- **Small Businesses** (primary) — Use automated video production and agentic AI systems to create commercial content efficiently.
- **Diabetes and Obesity Markets** (primary) — Use KetoAir to support measurement and management of ketosis-related health objectives.
- **Biotechnology and Pharmaceutical Organizations** (secondary) — May license, partner on, or develop applications from the company’s protein-design and CAR-T IP.
- **Research Institutions** (emerging) — Collaborate on biomedical research, as demonstrated by the sponsored MIT co-development program.

- Consumers seeking automated video and AI productivity tools
- Small businesses using SaaS video production services
- Diabetes and obesity markets interested in ketosis monitoring
- Wellness customers purchasing KetoAir through digital channels
- Biotech and pharmaceutical partners evaluating cellular-therapy IP

## Geography

Change Agents Corporation is headquartered in the United States and has U.S. operating entities alongside Avalon Shanghai, whose functional currency is the Chinese renminbi. KetoAir distribution rights cover North America, South America, the European Union, and the United Kingdom, creating a broad intended commercialization footprint. The company sells KetoAir through its website and social media, while its AI and intellectual-property activities can be delivered or commercialized across markets.

- United States headquarters and principal corporate operations
- China presence through Avalon Shanghai
- KetoAir rights cover North and South America
- KetoAir rights cover the EU and United Kingdom
- U.S. dollar reporting with RMB translation exposure

## Strategy

The company’s strategy is to build an AI-centered software business while commercializing KetoAir and advancing biomedical intellectual property. Near-term priorities include developing the automated video platform, expanding KetoAir sales across its distribution territories, and pursuing additional diagnostic applications. The company also aims to preserve option value from MIT-linked protein-design research, CAR-T technology, and generative-AI assets through future commercialization or partnerships.

- **Launch and scale automated video production SaaS** (short-term) — A recurring software model could provide a scalable commercial platform for consumers and small businesses.
- **Commercialize KetoAir** (short-term) — Digital sales and broad distribution rights provide an initial route to product revenue in health and wellness markets.
- **Expand diagnostic applications** (medium-term) — Additional uses could increase the addressable market for the breathalyzer technology.
- **Advance biomedical intellectual property** (medium-term) — Patent development and research partnerships could create licensing or commercialization opportunities.

- Develop an agentic AI automated video SaaS platform
- Commercialize KetoAir through digital channels
- Pursue additional diagnostic uses for KetoAir
- Advance MIT-linked QTY protein-design patent applications
- Continue development of CAR-T technology IP
- Expand generative-AI publishing and software assets

## Risks

The company remains exposed to commercialization, financing, and execution risk because its AI and diagnostic offerings are developing businesses and its biomedical assets require further advancement or partnering. Report disclosures identify substantial going-concern uncertainty, recurring losses, negative operating cash flow, and dependence on additional capital and revenue generation. Regulatory, intellectual-property, foreign-exchange, and Nasdaq-listing risks could further constrain commercialization and access to financing.

- **Going-concern and financing risk** [critical] — The company reports recurring losses, negative operating cash flow, and dependence on additional financing and revenue generation.
- **Commercialization risk** [high] — AI software and KetoAir must gain customer adoption, establish distribution, and compete with alternative products.
- **Regulatory and medical-device risk** [high] — KetoAir’s healthcare positioning and future diagnostic applications may require regulatory compliance and evidence.
- **Intellectual-property development risk** [high] — The value of MIT-linked protein-design and CAR-T programs depends on patents, validation, and future licensing or partnerships.
- **Nasdaq listing risk** [high] — Loss of exchange listing could reduce trading liquidity, investor access, and financing capacity.
- **Foreign-exchange risk** [medium] — Avalon Shanghai uses RMB as its functional currency, requiring translation into the company’s U.S. dollar reporting currency.

- Early-stage products may not achieve meaningful customer adoption
- Additional financing may be unavailable or highly dilutive
- Going-concern uncertainty reflects funding and revenue dependence
- FDA, healthcare, and product regulations may delay commercialization
- Patent applications may not yield enforceable commercial rights
- RMB translation and China exposure create foreign-exchange risk

## Accounting

The company prepares U.S. GAAP financial statements and relies heavily on estimates for intangible-asset lives, impairment, credit losses, deferred-tax valuation allowances, stock compensation, preferred-stock valuation, and warrant fair values. Derivative liabilities and convertible financing features can create substantial period-to-period fair-value changes, while foreign-currency translation for Avalon Shanghai affects accumulated other comprehensive income. Historical real-property rental revenue was accounted for outside ASC 606, and the going-concern assessment affects the presentation and recoverability analysis of assets and liabilities.

- **Intangible assets and impairment** — Can materially affect operating expenses, asset balances, and future earnings.
- **Derivative and warrant fair value** — Fair-value changes can create significant non-operating gains or losses.
- **Foreign-currency translation** — Exchange-rate movements affect accumulated comprehensive income and reported comprehensive loss.
- **Going-concern assessment** — Failure to continue as a going concern could affect asset recoverability and liability classification.
- **Revenue recognition** — Timing and classification of revenue depend on contract and activity type.

- Intangible useful lives affect amortization and reported earnings
- Impairment testing depends on forecasts and asset recoverability
- Warrant and derivative fair values can increase earnings volatility
- Convertible financing valuations require significant judgment
- RMB translation affects comprehensive income, not operating revenue
- Going-concern uncertainty affects asset and liability assessment

---

*Last updated: 2026-09-24T11:33:55.135116+00:00*